 |
 |
 |
 |
 |
 |
||
 |
 |
 |
 |
 |
| 3 | 1/1 | 返回列表 |
| 查看: 661 | 回復(fù): 2 | |||
狼行拂曉榮譽(yù)版主 (著名寫手)
~~~~
|
[交流]
Novo Nordisk to Initiate Phase 3a Development of Oral Semaglutide 已有2人參與
|
|
Novo Nordisk to Initiate Phase 3a Development of Oral Semaglutide, a Once-Daily Oral GLP-1 Analogue Bagsværd, Denmark, 26 August 2015 - Novo Nordisk today announced the decision to initiate a phase 3a programme with oral semaglutide; a once-daily oral formulation of the long-acting GLP-1 analogue semaglutide. The decision follows the encouraging results of the proof-of-concept phase 2 trial announced on 20 February 2015 and the subsequent consultations with regulatory authorities. Novo Nordisk intends to initiate a global phase 3a programme, named PIONEER, comprising seven trials with approximately 8,000 people with type 2 diabetes. The PIONEER programme will include six safety and efficacy trials and one trial for evaluating the cardio-vascular safety of oral semaglutide. The first trial in the programme is planned for initiation in first quarter of 2016 and will investigate the efficacy and safety of once-daily oral semaglutide doses of 3 mg, 7 mg and 14 mg, compared to once-daily oral anti-diabetic sitagliptin dose of 100 mg. The remaining six trials of the PIONEER programme are all expected to be initiated during 2016. In order to meet capacity requirements for current and future diabetes care products, including oral semaglutide, Novo Nordisk expects to invest an estimated 2 billion US dollars over the coming five years in two new production facilities; a new production facility for a range of active pharmaceutical ingredients in Clayton, North Carolina, US and a new drug-product facility in Måløv, Denmark. The final design and cost of the new production facilities will be presented for approval by the company's board of directors in 2016. "Delivering protein-based medicine like semaglutide in the form of a tablet and producing it on a large scale is a major challenge, and with the announcement today we have reached a significant milestone towards achieving that goal", said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. "We are excited about the opportunities oral semaglutide represents as a new oral anti-diabetic agent to further improve type 2 diabetes treatment". About Semaglutide Semaglutide (NN9924) is a new glucagon-like peptide-1 (GLP-1) analogue that can help people with type 2 diabetes achieve substantial lowering of blood glucose with a low risk of hypoglycaemia. In addition, semaglutide induces weight loss by decreasing appetite and food intake. The oral formulation of semaglutide is provided in a tablet formulation with SNAC, an absorption-enhancing excipient included in the Eligen® Carrier Concept. The Eligen® technology is licenced from Emisphere Technologies, Inc. Source: Novo Nordisk Posted: August 2015 |
回復(fù)此樓» 猜你喜歡
求調(diào)劑
已經(jīng)有1人回復(fù)
-
298求調(diào)劑一志愿中海洋
已經(jīng)有3人回復(fù)
-
藥物學(xué)論文潤(rùn)色/翻譯怎么收費(fèi)?
已經(jīng)有51人回復(fù)
-
藥學(xué)專碩調(diào)劑
已經(jīng)有0人回復(fù)
-
藥學(xué)調(diào)劑申請(qǐng)自薦信，一志愿中南大學(xué)
已經(jīng)有1人回復(fù)
-
藥學(xué)349專碩求調(diào)劑
已經(jīng)有1人回復(fù)
-
publcif的使用
已經(jīng)有0人回復(fù)
-
求調(diào)劑
已經(jīng)有2人回復(fù)
-
會(huì)計(jì)專碩求調(diào)劑
已經(jīng)有0人回復(fù)
-
《左乙拉西坦注射液制備工藝研究、質(zhì)量控制和穩(wěn)定性研究》下載
已經(jīng)有1人回復(fù)
-
新加坡國(guó)立大學(xué)藥學(xué)系化學(xué)生物學(xué)課題組招PhD
已經(jīng)有12人回復(fù)
voyager88
金蟲 (著名寫手)
- DRDEPI: 11
- 應(yīng)助: 584 (博士)
- 金幣: 2387
- 散金: 4182
- 紅花: 338
- 帖子: 1994
- 在線: 551.7小時(shí)
- 蟲號(hào): 1259270
- 注冊(cè): 2011-04-08
- 專業(yè): 藥劑學(xué)
2樓2015-09-01 13:52:11
GeniusCai
銅蟲 (初入文壇)
- 應(yīng)助: 0 (幼兒園)
- 金幣: 716.1
- 帖子: 42
- 在線: 16.2小時(shí)
- 蟲號(hào): 2362462
- 注冊(cè): 2013-03-20
- 性別: GG
- 專業(yè): 藥物化學(xué)
3樓2015-09-10 22:43:50
相關(guān)版塊跳轉(zhuǎn)
我要訂閱樓主 狼行拂曉 的主題更新
| 3 | 1/1 | 返回列表 |
| 最具人氣熱帖推薦 [查看全部] | 作者 | 回/看 | 最后發(fā)表 | |
|---|---|---|---|---|
|
[考研] 085600材料與化工求調(diào)劑 +6 | 緒幸與子 2026-03-17 | 6/300 |
|
|---|---|---|---|---|
|
|
[考研] 一志愿天大材料與化工（085600）總分338 +5 | 蔡大美女 2026-03-13 | 5/250 |
|
|
[考研] 332求調(diào)劑 +3 | ydfyh 2026-03-17 | 3/150 |
|
|
|
[考研] 267一志愿南京工業(yè)大學(xué)0817化工求調(diào)劑 +10 | SUICHILD 2026-03-12 | 10/500 |
|
|
|
[考研] 274求調(diào)劑 +6 | S.H1 2026-03-18 | 6/300 |
|
|
|
[考研] 求材料調(diào)劑 +10 | 隔壁陳先生 2026-03-12 | 10/500 |
|
|
|
[考研] 收復(fù)試調(diào)劑生 +4 | 雨后秋荷 2026-03-18 | 4/200 |
|
|
|
[考研]
 0854，計(jì)算機(jī)類招收調(diào)劑
+3
|
胡辣湯放糖 2026-03-15 | 6/300 |
|
|
|
[考研] 材料，紡織，生物（0856、0710），化學(xué)招生啦 +3 | Eember. 2026-03-17 | 9/450 |
|
|
|
[基金申請(qǐng)] 被我言中：新模板不強(qiáng)調(diào)格式了，假專家開始管格式了 +4 | beefly 2026-03-14 | 4/200 |
|
|
|
[考研] 本人考085602 化學(xué)工程 專碩 +16 | 不知道叫什么！ 2026-03-15 | 18/900 |
|
|
|
[考研] 梁成偉老師課題組歡迎你的加入 +8 | 一鴨鴨喲 2026-03-14 | 10/500 |
|
|
|
[考研] 一志愿南京大學(xué)，080500材料科學(xué)與工程，調(diào)劑 +4 | Jy? 2026-03-16 | 4/200 |
|
|
|
[考研] 318求調(diào)劑 +3 | Yanyali 2026-03-15 | 3/150 |
|
|
|
[考研] 0703一志愿211 285分求調(diào)劑 +5 | ly3471z 2026-03-13 | 5/250 |
|
|
|
[考研] 326求調(diào)劑 +3 | mlpqaz03 2026-03-15 | 3/150 |
|
|
|
[基金申請(qǐng)] 現(xiàn)在如何回避去年的某一個(gè)專家，不知道名字 +3 | zk200107 2026-03-12 | 6/300 |
|
|
|
[考研] 復(fù)試調(diào)劑 +4 | z1z2z3879 2026-03-14 | 5/250 |
|
|
|
[考研] 0856材料與化工301求調(diào)劑 +5 | 奕束光 2026-03-13 | 5/250 |
|
|
|
[考研] 308求調(diào)劑 +3 | 是Lupa啊 2026-03-12 | 3/150 |
|